Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tsubota LaboratoryTSE:4890 -0.42%63 EBIT per Share is 円-29.51 as of Mar. 2026. GuruFocus rates TSE:4890 with a GF Score™ of 63/100 and a GF Value™ of 円82.89 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 686 Medical Devices & Instruments companies, Tsubota Laboratory ranks worse than 145772.45% on this metric.
Tsubota Laboratory's EBIT per Share for the
six
months ended in Mar. 2026 was 円-16.57.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円-29.51.
During the past 12 months, the average EBIT per Share Growth Rate of Tsubota Laboratory was -437.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Tsubota Laboratory's EBIT per Share or its related term are showing as below:
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Tsubota Laboratory was 123.50% per year. The lowest was 14.60% per year. And the median was 69.05% per year.
TSE:4890's 3-Year EBIT Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.25 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Tsubota Laboratory (TSE:4890) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Tsubota Laboratory EBIT per Share Related Terms
Tsubota Laboratory EBIT per Share Historical Data
* Premium members only.
The historical data trend for Tsubota Laboratory's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円-29.51
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tsubota Laboratory (TSE:4890) has a EBIT per Share of 円-29.51 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Tsubota Laboratory and its competitors. According to the industry distribution chart, Tsubota Laboratory ranks #999999 out of 686 companies in the Medical Devices & Instruments industry.
Is Tsubota Laboratory's EBIT per Share too high?
Tsubota Laboratory's current EBIT per Share is 円-29.51. Based on the distribution chart, Tsubota Laboratory ranks #999999 out of 686 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Tsubota Laboratory has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tsubota Laboratory's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Tsubota Laboratory ranks #999999 out of 686 companies for EBIT per Share. This places Tsubota Laboratory in the lower half of its industry. The industry median EBIT per Share is 9.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.25, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Tsubota Laboratory and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tsubota Laboratory's current EBIT per Share is 円-29.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tsubota Laboratory stock overvalued right now?
Based on GuruFocus' analysis, Tsubota Laboratory (TSE:4890) is currently considered Significantly Overvalued. The stock's GF Value™ is 円82.89, compared to a current price of 円236.00 — trading 184.7% above its estimated fair value. The current EBIT per Share is 円-29.51. Tsubota Laboratory's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Tsubota Laboratory (TSE:4890), the current EBIT per Share is 円-29.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tsubota Laboratory (TSE:4890) Overvalued in 2026?
Based on GuruFocus' analysis, Tsubota Laboratory stock appears to be overvalued.
The current stock price of 円236.00 is trading 184.7% above its estimated GF Value™ of 円82.89.
GuruFocus considers Tsubota Laboratory to be Significantly Overvalued.
Key valuation signals for TSE:4890:
EBIT per Share: 円-29.51
GF Value™: 円82.89 vs. price of 円236.00 (184.7% above fair value)
No single metric tells the full story. See the TSE:4890 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tsubota Laboratory Inc is engaged in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia.
63GF Score
Get the complete analysis for TSE:4890
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4890 has been successfully added to your 
